Details of the Drug Combinations

General Information of This Drug (ID: DMLWYJB)

Drug Name
JNK-IN-8   DMLWYJB
Synonyms
JNK-IN-8; 1410880-22-6; JNK Inhibitor XVI; 3-[[(E)-4-(dimethylamino)but-2-enoyl]amino]-N-[3-methyl-4-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide; JNK-IN8; GTPL8058; CHEMBL2216824; SCHEMBL14979761; BDBM86633; DTXSID40720937; CHEBI:124918; MolPort-035-395-752; EX-A2206; BCP09744; ZINC89464842; s4901; AKOS030526496; SB19427; CS-0601; NCGC00386243-05; HY-13319; BC600656; Y1469; SW219193-1; W-5897; J-007458; 3-{[(2E)-4-(Dimethylamino)but-2-enoyl]amino}-N-(3-methyl-4-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

282 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
ABIRATERONE + JNK-IN-8 DCI8DK2 ABIRATERONE Renal cell carcinoma (Cell Line: SN12C) [2]
ABIRATERONE + JNK-IN-8 DCQVIOE ABIRATERONE Colon carcinoma (Cell Line: KM12) [3]
ABIRATERONE + JNK-IN-8 DCJSKRE ABIRATERONE Adenocarcinoma (Cell Line: HCT-15) [4]
ABIRATERONE + JNK-IN-8 DCDUDM8 ABIRATERONE High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
Amonafide + JNK-IN-8 DCFIHSQ Amonafide Adenocarcinoma (Cell Line: HT29) [2]
Anastrozole + JNK-IN-8 DCDTU3W Anastrozole Adenocarcinoma (Cell Line: HCC-2998) [2]
Anastrozole + JNK-IN-8 DC8YFWW Anastrozole Chronic myelogenous leukemia (Cell Line: K-562) [2]
Arfolitixorin + JNK-IN-8 DC3TQZ2 Arfolitixorin Astrocytoma (Cell Line: SNB-19) [2]
BIO-300 + JNK-IN-8 DCFO55S BIO-300 Anaplastic large cell lymphoma (Cell Line: SR) [2]
Bleomycin + JNK-IN-8 DCZI95D Bleomycin Adenocarcinoma (Cell Line: HT29) [4]
Cabazitaxel + JNK-IN-8 DCSJYRS Cabazitaxel Adenocarcinoma (Cell Line: DU-145) [2]
Cabazitaxel + JNK-IN-8 DCNXMJU Cabazitaxel Adenocarcinoma (Cell Line: A549) [2]
Cabazitaxel + JNK-IN-8 DC5AFQ5 Cabazitaxel Adenocarcinoma (Cell Line: HCC-2998) [2]
Cabazitaxel + JNK-IN-8 DCJH2E0 Cabazitaxel Adenocarcinoma (Cell Line: HCT-15) [2]
Cabazitaxel + JNK-IN-8 DC3NKY4 Cabazitaxel Adenocarcinoma (Cell Line: HCT116) [2]
Cabazitaxel + JNK-IN-8 DCUZ6F8 Cabazitaxel Adenocarcinoma (Cell Line: HT29) [2]
Cabazitaxel + JNK-IN-8 DC72DKY Cabazitaxel Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Cabazitaxel + JNK-IN-8 DCN7O8T Cabazitaxel Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Cabazitaxel + JNK-IN-8 DC61GXS Cabazitaxel Anaplastic large cell lymphoma (Cell Line: SR) [2]
Cabazitaxel + JNK-IN-8 DCSRSU9 Cabazitaxel Astrocytoma (Cell Line: SNB-19) [2]
Cabazitaxel + JNK-IN-8 DC9M25H Cabazitaxel Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Cabazitaxel + JNK-IN-8 DCOIQA9 Cabazitaxel High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [2]
Cabazitaxel + JNK-IN-8 DC84H27 Cabazitaxel Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Cabazitaxel + JNK-IN-8 DCF7B7I Cabazitaxel Lung adenocarcinoma (Cell Line: NCI-H522) [2]
Cabazitaxel + JNK-IN-8 DCD5CIT Cabazitaxel Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [2]
Cabazitaxel + JNK-IN-8 DCSQEOL Cabazitaxel Non-small cell lung carcinoma (Cell Line: HOP-92) [2]
Cabazitaxel + JNK-IN-8 DCP3KRB Cabazitaxel Prostate carcinoma (Cell Line: PC-3) [2]
Cabazitaxel + JNK-IN-8 DC3SF5P Cabazitaxel Renal cell carcinoma (Cell Line: SN12C) [2]
Cabazitaxel + JNK-IN-8 DCMOWN3 Cabazitaxel Carcinoma (Cell Line: RXF 393) [3]
Cabazitaxel + JNK-IN-8 DC7PUL6 Cabazitaxel Colon carcinoma (Cell Line: KM12) [3]
Crizotinib + JNK-IN-8 DCD1KGQ Crizotinib Adenocarcinoma (Cell Line: HCT-15) [2]
Crizotinib + JNK-IN-8 DCVIJOD Crizotinib Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Crizotinib + JNK-IN-8 DCBW9HN Crizotinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
Crizotinib + JNK-IN-8 DC9YEW4 Crizotinib Glioma (Cell Line: SF-539) [2]
Crizotinib + JNK-IN-8 DC51L0G Crizotinib Large cell lung carcinoma (Cell Line: NCI-H460) [2]
Crizotinib + JNK-IN-8 DCIRVHW Crizotinib Malignant melanoma (Cell Line: LOX IMVI) [2]
Crizotinib + JNK-IN-8 DCU5BCZ Crizotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [2]
Crizotinib + JNK-IN-8 DCIMIR4 Crizotinib Renal cell carcinoma (Cell Line: SN12C) [2]
Crizotinib + JNK-IN-8 DCH7QAO Crizotinib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Crizotinib + JNK-IN-8 DC7RM1Y Crizotinib Colon carcinoma (Cell Line: KM12) [3]
Dacarbazine + JNK-IN-8 DC29JEH Dacarbazine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Dacarbazine + JNK-IN-8 DCD13CQ Dacarbazine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
Dacarbazine + JNK-IN-8 DCRQDCI Dacarbazine High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [2]
Dacarbazine + JNK-IN-8 DC8CL5B Dacarbazine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
Epirubicin + JNK-IN-8 DC86P9G Epirubicin Renal cell carcinoma (Cell Line: SN12C) [2]
Epirubicin + JNK-IN-8 DCF2WAF Epirubicin Carcinoma (Cell Line: RXF 393) [3]
Gefitinib + JNK-IN-8 DCWFS9C Gefitinib Adenocarcinoma (Cell Line: HCC-2998) [2]
Gefitinib + JNK-IN-8 DC3YGSF Gefitinib Chronic myelogenous leukemia (Cell Line: K-562) [2]
Indazole derivative 5 + JNK-IN-8 DC0XKUR Indazole derivative 5 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Indazole derivative 5 + JNK-IN-8 DCRDP1H Indazole derivative 5 Anaplastic large cell lymphoma (Cell Line: SR) [2]
Indazole derivative 5 + JNK-IN-8 DCOHTNM Indazole derivative 5 Renal cell carcinoma (Cell Line: SN12C) [2]
Indazole derivative 5 + JNK-IN-8 DCF3PJU Indazole derivative 5 Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Indazole derivative 5 + JNK-IN-8 DCSCXT6 Indazole derivative 5 Colon carcinoma (Cell Line: KM12) [3]
Indazole derivative 5 + JNK-IN-8 DCGB05J Indazole derivative 5 Adenocarcinoma (Cell Line: HCT-15) [4]
Indazole derivative 5 + JNK-IN-8 DCE4SQR Indazole derivative 5 Large cell lung carcinoma (Cell Line: NCI-H460) [4]
Indazole derivative 5 + JNK-IN-8 DCIUNWV Indazole derivative 5 Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
JNK-IN-8 + Pentostatin DC6NKMY Pentostatin Clear cell renal cell carcinoma (Cell Line: A498) [2]
JNK-IN-8 + Pentostatin DC3E0NU Pentostatin Renal cell carcinoma (Cell Line: SN12C) [2]
JNK-IN-8 + Ixabepilone DCKKQOJ Ixabepilone Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Ixabepilone DCBS631 Ixabepilone Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + Dactinomycin DCFAPJJ Dactinomycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
JNK-IN-8 + Dactinomycin DC2EVK0 Dactinomycin Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Dactinomycin DCB8IS9 Dactinomycin Astrocytoma (Cell Line: SNB-19) [2]
JNK-IN-8 + Dactinomycin DCWPIYJ Dactinomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
JNK-IN-8 + Dactinomycin DCPHBW9 Dactinomycin Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Dactinomycin DCHXIRT Dactinomycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
JNK-IN-8 + Lapatinib DCIW3X1 Lapatinib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
JNK-IN-8 + PMID28460551-Compound-2 DCFR93L PMID28460551-Compound-2 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + PMID28460551-Compound-2 DCDOJMS PMID28460551-Compound-2 Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
JNK-IN-8 + PMID28460551-Compound-2 DCYB7AT PMID28460551-Compound-2 Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Crizotinib DC0GXCU Crizotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Crizotinib DC8TV3I Crizotinib Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + Methotrexate DCH108N Methotrexate Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Arsenic trioxide DC7ANRV Arsenic trioxide Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Arsenic trioxide DCZSXH9 Arsenic trioxide Glioma (Cell Line: SF-539) [2]
JNK-IN-8 + Arsenic trioxide DCQCRBM Arsenic trioxide Plasma cell myeloma (Cell Line: RPMI-8226) [2]
JNK-IN-8 + Vemurafenib DCPGDSI Vemurafenib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Plicamycin DCR6O9H Plicamycin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + Plicamycin DCQU193 Plicamycin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
JNK-IN-8 + Plicamycin DC30W15 Plicamycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
JNK-IN-8 + Plicamycin DC4Z994 Plicamycin Chronic myelogenous leukemia (Cell Line: K-562) [2]
JNK-IN-8 + Plicamycin DCQBYA6 Plicamycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
JNK-IN-8 + Plicamycin DC13VM3 Plicamycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
JNK-IN-8 + Plicamycin DC73RRS Plicamycin Renal cell carcinoma (Cell Line: UO-31) [2]
JNK-IN-8 + Nilotinib DCVTUUG Nilotinib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Nilotinib DCN2RIF Nilotinib Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + 10-hydroxycamptothecin DCFFPUL 10-hydroxycamptothecin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + 10-hydroxycamptothecin DCDUOLY 10-hydroxycamptothecin Papillary renal cell carcinoma (Cell Line: ACHN) [2]
JNK-IN-8 + Topetecan DC2SNYV Topetecan Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + Topetecan DCVB2WY Topetecan Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Topetecan DCJ3B5G Topetecan Papillary renal cell carcinoma (Cell Line: ACHN) [2]
JNK-IN-8 + Pralatrexate DCHAQPE Pralatrexate Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + Docetaxel DCVZUF5 Docetaxel Papillary renal cell carcinoma (Cell Line: ACHN) [2]
JNK-IN-8 + Bendamustine hydrochloride DCXGYLZ Bendamustine hydrochloride Renal cell carcinoma (Cell Line: UO-31) [2]
JNK-IN-8 + Letrozole DCVIHU6 Letrozole Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + Mitomycin DCSGTR8 Mitomycin Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
JNK-IN-8 + Mitomycin DCN779B Mitomycin Glioma (Cell Line: SF-268) [2]
JNK-IN-8 + SY-1425 DCSOY7Y SY-1425 Plasma cell myeloma (Cell Line: RPMI-8226) [2]
JNK-IN-8 + Vincristine DCEEHZV Vincristine Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + Vincristine DCKJ2JB Vincristine Clear cell renal cell carcinoma (Cell Line: A498) [2]
JNK-IN-8 + Vincristine DCWP1FH Vincristine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Idarubicin DCKGG36 Idarubicin Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Bleomycin DCUVY2I Bleomycin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
JNK-IN-8 + Bleomycin DCFM8G7 Bleomycin Chronic myelogenous leukemia (Cell Line: K-562) [2]
JNK-IN-8 + Bleomycin DCW706A Bleomycin Plasma cell myeloma (Cell Line: RPMI-8226) [2]
JNK-IN-8 + Bortezomib DC77C9Q Bortezomib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + Bortezomib DCKAULV Bortezomib Astrocytoma (Cell Line: U251) [2]
JNK-IN-8 + Bortezomib DCGJYTS Bortezomib Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Bortezomib DC6OBHX Bortezomib Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
JNK-IN-8 + Bortezomib DCZ5TDA Bortezomib Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + Valrubicin DCXIS4L Valrubicin Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + Valrubicin DC9GXZF Valrubicin Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
JNK-IN-8 + Valrubicin DCSNOA3 Valrubicin Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
JNK-IN-8 + Valrubicin DCMU4YJ Valrubicin Renal cell carcinoma (Cell Line: SN12C) [2]
JNK-IN-8 + Chlorambucil DCB0S0W Chlorambucil Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + Chlorambucil DC2GVQJ Chlorambucil Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Sorafenib DC6GNLY Sorafenib Astrocytoma (Cell Line: SNB-19) [2]
JNK-IN-8 + Sorafenib DCCS8J8 Sorafenib Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + ER819762 DCTNMXH ER819762 Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + ER819762 DCY55RQ ER819762 Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + ER819762 DCD6RVL ER819762 Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + ER819762 DC4WZ9Z ER819762 Clear cell renal cell carcinoma (Cell Line: CAKI-1) [2]
JNK-IN-8 + Romidepsin DCFCRQJ Romidepsin Glioblastoma (Cell Line: SNB-75) [2]
JNK-IN-8 + Azacitidine DCQYBBO Azacitidine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
JNK-IN-8 + Azacitidine DC7E6R9 Azacitidine Plasma cell myeloma (Cell Line: RPMI-8226) [2]
JNK-IN-8 + Pomalidomide DCIDAAE Pomalidomide Glioma (Cell Line: SF-295) [2]
JNK-IN-8 + Pomalidomide DC6CA0M Pomalidomide Renal cell carcinoma (Cell Line: SN12C) [2]
JNK-IN-8 + Vinflunine DCUIH7W Vinflunine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
JNK-IN-8 + Vinflunine DCC315T Vinflunine Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
JNK-IN-8 + Mepacrine DC67NXJ Mepacrine Renal cell carcinoma (Cell Line: UO-31) [2]
JNK-IN-8 + FORMESTANE DCWTGBJ FORMESTANE Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
JNK-IN-8 + Aminolevulinic Acid Hydrochloride DCBKGCS Aminolevulinic Acid Hydrochloride Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Digitoxin DC09BFW Digitoxin Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Dasatinib DC2299O Dasatinib Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
JNK-IN-8 + Dasatinib DCU02UX Dasatinib Anaplastic large cell lymphoma (Cell Line: SR) [2]
JNK-IN-8 + Dasatinib DCPBTVR Dasatinib Childhood T acute lymphoblastic leukemia (Cell Line: CCRF-CEM) [2]
JNK-IN-8 + Dasatinib DCGMPEN Dasatinib Papillary renal cell carcinoma (Cell Line: ACHN) [2]
JNK-IN-8 + Dasatinib DCZFMGV Dasatinib Renal cell carcinoma (Cell Line: UO-31) [2]
JNK-IN-8 + Dactinomycin DCB10LM Dactinomycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
JNK-IN-8 + Dactinomycin DCSMUWP Dactinomycin Carcinoma (Cell Line: RXF 393) [3]
JNK-IN-8 + Dactinomycin DCLW4UO Dactinomycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
JNK-IN-8 + Dactinomycin DCSDPHR Dactinomycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
JNK-IN-8 + Dactinomycin DCH2Y36 Dactinomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
JNK-IN-8 + DFN-15 DCYUKX3 DFN-15 Colon carcinoma (Cell Line: KM12) [3]
JNK-IN-8 + PMID28460551-Compound-2 DCMDOJQ PMID28460551-Compound-2 Colon carcinoma (Cell Line: KM12) [3]
JNK-IN-8 + Arsenic trioxide DCFGRTD Arsenic trioxide Colon carcinoma (Cell Line: KM12) [3]
JNK-IN-8 + Plicamycin DCJ5VQZ Plicamycin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
JNK-IN-8 + Plicamycin DC538EX Plicamycin Carcinoma (Cell Line: RXF 393) [3]
JNK-IN-8 + Plicamycin DCQBZ79 Plicamycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
JNK-IN-8 + Plicamycin DCIVFS0 Plicamycin Invasive ductal carcinoma (Cell Line: BT-549) [3]
JNK-IN-8 + Plicamycin DC0A5GT Plicamycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
JNK-IN-8 + Mitomycin DCR145Y Mitomycin Colon adenocarcinoma (Cell Line: COLO 205) [3]
JNK-IN-8 + Mitomycin DCP7DFI Mitomycin Invasive ductal carcinoma (Cell Line: HS 578T) [3]
JNK-IN-8 + TEM DCAK45W TEM Colon carcinoma (Cell Line: KM12) [3]
JNK-IN-8 + Bleomycin DCC83AV Bleomycin Carcinoma (Cell Line: MCF7) [3]
JNK-IN-8 + Bortezomib DCZI0IY Bortezomib Colon adenocarcinoma (Cell Line: COLO 205) [3]
JNK-IN-8 + Romidepsin DCDBKLG Romidepsin Invasive ductal carcinoma (Cell Line: BT-549) [3]
JNK-IN-8 + Digitoxin DCLES7L Digitoxin Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
JNK-IN-8 + Fulvestrant DCOEBRZ Fulvestrant High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
JNK-IN-8 + Hepzato DC5LWL6 Hepzato High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
JNK-IN-8 + Ixabepilone DC98LV4 Ixabepilone Adenocarcinoma (Cell Line: DU-145) [4]
JNK-IN-8 + Ixabepilone DCKEDYN Ixabepilone Adenocarcinoma (Cell Line: OVCAR3) [4]
JNK-IN-8 + Ixabepilone DCR7JUH Ixabepilone Adenocarcinoma (Cell Line: HCC-2998) [4]
JNK-IN-8 + Ixabepilone DCKLK19 Ixabepilone Adenocarcinoma (Cell Line: HCT-15) [4]
JNK-IN-8 + Ixabepilone DC7RSZI Ixabepilone Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + Ixabepilone DCE5FH5 Ixabepilone Malignant melanoma (Cell Line: LOX IMVI) [4]
JNK-IN-8 + Ixabepilone DC3MQ4J Ixabepilone Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Dactinomycin DC5Q368 Dactinomycin Adenocarcinoma (Cell Line: SW-620) [4]
JNK-IN-8 + Dactinomycin DCBFRXR Dactinomycin Adenocarcinoma (Cell Line: HCT116) [4]
JNK-IN-8 + Dactinomycin DCUBOB6 Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
JNK-IN-8 + Dactinomycin DCHSS1I Dactinomycin Cutaneous melanoma (Cell Line: SK-MEL-5) [4]
JNK-IN-8 + Dactinomycin DC2PC1X Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-5) [4]
JNK-IN-8 + Dactinomycin DCH52CM Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-8) [4]
JNK-IN-8 + Dactinomycin DC08OE4 Dactinomycin High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
JNK-IN-8 + Dactinomycin DCKM46T Dactinomycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
JNK-IN-8 + Dactinomycin DCX5OR9 Dactinomycin Lung adenocarcinoma (Cell Line: EKVX) [4]
JNK-IN-8 + Dactinomycin DCFC7T4 Dactinomycin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
JNK-IN-8 + Dactinomycin DC50CYZ Dactinomycin Malignant melanoma (Cell Line: LOX IMVI) [4]
JNK-IN-8 + DFN-15 DC51BU2 DFN-15 Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + PMID28460551-Compound-2 DCICDMD PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
JNK-IN-8 + PMID28460551-Compound-2 DC01DSA PMID28460551-Compound-2 Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + PMID28460551-Compound-2 DC1ALVZ PMID28460551-Compound-2 Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
JNK-IN-8 + Crizotinib DCPXNC8 Crizotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + LIAROZOLE DCMR3PF LIAROZOLE Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
JNK-IN-8 + Methotrexate DCBMDY4 Methotrexate Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
JNK-IN-8 + Arsenic trioxide DCNUQ6A Arsenic trioxide Amelanotic melanoma (Cell Line: MDA-MB-435) [4]
JNK-IN-8 + Arsenic trioxide DC5GLT1 Arsenic trioxide Cutaneous melanoma (Cell Line: SK-MEL-28) [4]
JNK-IN-8 + Arsenic trioxide DCVDI1I Arsenic trioxide Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
JNK-IN-8 + Vemurafenib DC9IN8M Vemurafenib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Plicamycin DCVX36Z Plicamycin Adenocarcinoma (Cell Line: DU-145) [4]
JNK-IN-8 + Plicamycin DCT42ZG Plicamycin Adenocarcinoma (Cell Line: HCT116) [4]
JNK-IN-8 + Plicamycin DC3SVAY Plicamycin Amelanotic melanoma (Cell Line: M14) [4]
JNK-IN-8 + Plicamycin DCM6G76 Plicamycin Large cell lung carcinoma (Cell Line: NCI-H460) [4]
JNK-IN-8 + Plicamycin DC426J8 Plicamycin Lung adenocarcinoma (Cell Line: EKVX) [4]
JNK-IN-8 + Plicamycin DC28G73 Plicamycin Lung adenocarcinoma (Cell Line: NCI-H522) [4]
JNK-IN-8 + Plicamycin DCDRL8M Plicamycin Malignant melanoma (Cell Line: UACC62) [4]
JNK-IN-8 + Nilotinib DCFVOPC Nilotinib Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + Nilotinib DCF8M2B Nilotinib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Nilotinib DC0V2OF Nilotinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
JNK-IN-8 + 10-hydroxycamptothecin DCB7XO8 10-hydroxycamptothecin Adenocarcinoma (Cell Line: NCIH23) [4]
JNK-IN-8 + 10-hydroxycamptothecin DCXCIIZ 10-hydroxycamptothecin Amelanotic melanoma (Cell Line: M14) [4]
JNK-IN-8 + Pralatrexate DCLU7PJ Pralatrexate Adenocarcinoma (Cell Line: OVCAR3) [4]
JNK-IN-8 + Pralatrexate DCDOLZV Pralatrexate Adenocarcinoma (Cell Line: HCT-15) [4]
JNK-IN-8 + Pralatrexate DCRMT6E Pralatrexate Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + Pralatrexate DCAD8CH Pralatrexate Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Pralatrexate DCQ3P75 Pralatrexate Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
JNK-IN-8 + SCH 727965 DC8ROPX SCH 727965 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Docetaxel DCBVRRC Docetaxel Amelanotic melanoma (Cell Line: M14) [4]
JNK-IN-8 + Bendamustine hydrochloride DCNQBGM Bendamustine hydrochloride Adenocarcinoma (Cell Line: A549) [4]
JNK-IN-8 + Bendamustine hydrochloride DCLRRNL Bendamustine hydrochloride Adenocarcinoma (Cell Line: HCT116) [4]
JNK-IN-8 + Bendamustine hydrochloride DCMU8JX Bendamustine hydrochloride High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
JNK-IN-8 + Bendamustine hydrochloride DCKOYSQ Bendamustine hydrochloride Large cell lung carcinoma (Cell Line: NCI-H460) [4]
JNK-IN-8 + Bendamustine hydrochloride DC3HV3Y Bendamustine hydrochloride Melanoma (Cell Line: MALME-3M) [4]
JNK-IN-8 + Mitomycin DC11U4I Mitomycin High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
JNK-IN-8 + Mitomycin DCQ8XVZ Mitomycin Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
JNK-IN-8 + SY-1425 DCA31EE SY-1425 Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
JNK-IN-8 + Vincristine DCRKYAV Vincristine Adenocarcinoma (Cell Line: DU-145) [4]
JNK-IN-8 + Vincristine DCRMNJ0 Vincristine Adenocarcinoma (Cell Line: HCT-15) [4]
JNK-IN-8 + TEM DCF5G66 TEM Adenocarcinoma (Cell Line: SW-620) [4]
JNK-IN-8 + TEM DC4RIDX TEM Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Bleomycin DCKB2BN Bleomycin Melanoma (Cell Line: SK-MEL-2) [4]
JNK-IN-8 + Bortezomib DC3POYU Bortezomib Adenocarcinoma (Cell Line: DU-145) [4]
JNK-IN-8 + Bortezomib DCQMW2H Bortezomib Adenocarcinoma (Cell Line: A549) [4]
JNK-IN-8 + Bortezomib DCVRC8X Bortezomib Adenocarcinoma (Cell Line: HCT-15) [4]
JNK-IN-8 + Bortezomib DCTPJVR Bortezomib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
JNK-IN-8 + Bortezomib DC5OOK2 Bortezomib Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Valrubicin DC2RNEK Valrubicin Lung adenocarcinoma (Cell Line: EKVX) [4]
JNK-IN-8 + Sorafenib DCRH3V6 Sorafenib Adenocarcinoma (Cell Line: HCT116) [4]
JNK-IN-8 + Sorafenib DCAEUZ4 Sorafenib Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + ER819762 DCMOKNQ ER819762 Amelanotic melanoma (Cell Line: M14) [4]
JNK-IN-8 + ER819762 DCIWP8K ER819762 Minimally invasive lung adenocarcinoma (Cell Line: NCI-H322M) [4]
JNK-IN-8 + Romidepsin DCZJW9L Romidepsin Lung adenocarcinoma (Cell Line: MDA-MB-231) [4]
JNK-IN-8 + Romidepsin DCAMQ9K Romidepsin Lung adenocarcinoma (Cell Line: EKVX) [4]
JNK-IN-8 + Romidepsin DCNZLHO Romidepsin Malignant melanoma (Cell Line: LOX IMVI) [4]
JNK-IN-8 + Romidepsin DCSD43C Romidepsin Melanoma (Cell Line: MALME-3M) [4]
JNK-IN-8 + Romidepsin DCXB5EW Romidepsin Mixed endometrioid and clear cell carcinoma (Cell Line: IGROV1) [4]
JNK-IN-8 + Azacitidine DCFTI2D Azacitidine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
JNK-IN-8 + Azacitidine DCWUT0I Azacitidine Malignant melanoma (Cell Line: UACC62) [4]
JNK-IN-8 + Pomalidomide DCNCMFT Pomalidomide Malignant melanoma (Cell Line: UACC62) [4]
JNK-IN-8 + Vinflunine DCF21IE Vinflunine High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
JNK-IN-8 + Mercaptopurine DCR8W35 Mercaptopurine Lung adenocarcinoma (Cell Line: EKVX) [4]
JNK-IN-8 + Mepacrine DCOMS2B Mepacrine Lung adenocarcinoma (Cell Line: EKVX) [4]
JNK-IN-8 + Mepacrine DCJS465 Mepacrine Lung adenocarcinoma (Cell Line: NCI-H522) [4]
JNK-IN-8 + Fludarabine DCKK6VM Fludarabine Large cell lung carcinoma (Cell Line: NCI-H460) [4]
JNK-IN-8 + FORMESTANE DCRLMGR FORMESTANE Adenocarcinoma (Cell Line: OVCAR3) [4]
JNK-IN-8 + FORMESTANE DCZL2CP FORMESTANE High grade ovarian serous adenocarcinoma (Cell Line: NCI\\/ADR-RES) [4]
JNK-IN-8 + FORMESTANE DCPW4QF FORMESTANE Lung adenocarcinoma (Cell Line: HOP-62) [4]
JNK-IN-8 + Busulfan DCBHCJV Busulfan High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
JNK-IN-8 + Dasatinib DCU3682 Dasatinib High grade ovarian serous adenocarcinoma (Cell Line: OVCAR-4) [4]
Ruxolitinib + JNK-IN-8 DCUZNS3 Ruxolitinib Renal cell carcinoma (Cell Line: SN12C) [2]
Ruxolitinib + JNK-IN-8 DCV8BAK Ruxolitinib Colon carcinoma (Cell Line: KM12) [3]
Ruxolitinib + JNK-IN-8 DC3FFPC Ruxolitinib Adenocarcinoma (Cell Line: DU-145) [4]
Ruxolitinib + JNK-IN-8 DCFJZEF Ruxolitinib Lung adenocarcinoma (Cell Line: NCI-H522) [4]
Ruxolitinib + JNK-IN-8 DCPVPTA Ruxolitinib Malignant melanoma (Cell Line: LOX IMVI) [4]
Ruxolitinib + JNK-IN-8 DC79PLS Ruxolitinib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Thioguanine + JNK-IN-8 DCZ7POI Thioguanine Adult T acute lymphoblastic leukemia (Cell Line: MOLT-4) [2]
Thioguanine + JNK-IN-8 DCUT1BC Thioguanine Anaplastic large cell lymphoma (Cell Line: SR) [2]
Thioguanine + JNK-IN-8 DCTIVH8 Thioguanine Astrocytoma (Cell Line: SNB-19) [2]
Thioguanine + JNK-IN-8 DC0UH06 Thioguanine Clear cell renal cell carcinoma (Cell Line: 786-0) [2]
Thioguanine + JNK-IN-8 DC1ZTTT Thioguanine Glioma (Cell Line: SF-295) [2]
Thioguanine + JNK-IN-8 DC5XQBZ Thioguanine Invasive ductal carcinoma (Cell Line: BT-549) [3]
Thioguanine + JNK-IN-8 DCVIEMP Thioguanine Pleural epithelioid mesothelioma (Cell Line: NCI-H226) [4]
Topotecan + JNK-IN-8 DC6HTVH Topotecan Astrocytoma (Cell Line: SNB-19) [4]
Trifluridine + JNK-IN-8 DC1VCKH Trifluridine Adenocarcinoma (Cell Line: HT29) [4]
Uracil mustard + JNK-IN-8 DCMZT8V Uracil mustard Adult acute myeloid leukemia (Cell Line: HL-60(TB)) [2]
Uracil mustard + JNK-IN-8 DCNJL0X Uracil mustard Anaplastic large cell lymphoma (Cell Line: SR) [2]
Vandetanib + JNK-IN-8 DC365KS Vandetanib Adenocarcinoma (Cell Line: HCT-15) [4]
Vandetanib + JNK-IN-8 DCW21YQ Vandetanib Chronic myelogenous leukemia (Cell Line: K-562) [4]
Vandetanib + JNK-IN-8 DC86MMQ Vandetanib Glioma (Cell Line: SF-539) [4]
Vandetanib + JNK-IN-8 DC9MKHZ Vandetanib Malignant melanoma (Cell Line: LOX IMVI) [4]
Vandetanib + JNK-IN-8 DCDHR49 Vandetanib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vemurafenib + JNK-IN-8 DCFUZDP Vemurafenib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vemurafenib + JNK-IN-8 DC69IXT Vemurafenib Glioma (Cell Line: SF-539) [4]
Vemurafenib + JNK-IN-8 DCA97BY Vemurafenib Malignant melanoma (Cell Line: LOX IMVI) [4]
Vemurafenib + JNK-IN-8 DC8G7JL Vemurafenib Melanoma (Cell Line: MALME-3M) [4]
Vemurafenib + JNK-IN-8 DCVUFQ5 Vemurafenib Renal cell carcinoma (Cell Line: SN12C) [4]
Vismodegib + JNK-IN-8 DC3ML9O Vismodegib Breast adenocarcinoma (Cell Line: MDA-MB-468) [3]
Vismodegib + JNK-IN-8 DCERNR2 Vismodegib Adenocarcinoma (Cell Line: DU-145) [4]
Vismodegib + JNK-IN-8 DC5NWZ1 Vismodegib Glioma (Cell Line: SF-539) [4]
Vismodegib + JNK-IN-8 DCVFMUO Vismodegib Non-small cell lung carcinoma (Cell Line: HOP-92) [4]
Vismodegib + JNK-IN-8 DCZLVHK Vismodegib Ovarian serous cystadenocarcinoma (Cell Line: SK-OV-3) [4]
Vismodegib + JNK-IN-8 DCLPE7N Vismodegib Renal cell carcinoma (Cell Line: SN12C) [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 282 DrugCom(s)

References

1 Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
2 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
3 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
4 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.